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Abstract
Background: Long-term follow-up studies of people with schizophrenia report stability of
cognitive performance; less is known about any shorter-term changes in cognitive function.
Methods: This longitudinal study aimed to establish whether there was stability, improvement or
decline in memory and executive functions over four assessments undertaken prospectively in one
year. Cognitive performance was assessed during randomized controlled trials of first- and second-
generation antipsychotic medication. Analyses used a latent growth modeling approach, so that
individuals who missed some testing occasions could be included and trajectories of cognitive
change explored despite missing data.
Results: Over the year there was significant decline in spatial recognition but no change in pattern
recognition or motor speed. Improvement was seen in planning and spatial working memory tasks;
this may reflect improved strategy use with practice. There were significant individual differences
in the initial level of performance on all tasks but not in rate of change; the latter may have been
due to sample size limitations. Age, sex, premorbid IQ and drug class allocation explained significant
variation in level of performance but could not predict change. Patients randomized to first-
generation drugs improved more quickly than other groups on the planning task.
Conclusion: We conclude that cognitive change is present in schizophrenia but the magnitude of
change is small when compared with the large differences in cognitive function that exist between
patients. Analyses that retain patients who drop out of longitudinal studies, as well as those who
complete testing protocols, are important to our understanding of cognition in schizophrenia.
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The neurodevelopmental model of schizophrenia sug-
gests that cognitive deficits result from aberrant early
brain development [1-3], but it remains possible that fur-
ther cognitive change occurs once the disease develops.
Longitudinal studies generally show that cognitive deficits
are stable over long periods in chronic schizophrenia
although there is evidence for decline in elderly institu-
tionalised patients [4-6]. However these studies demon-
strating cognitive stability usually involve a baseline
assessment and a single follow-up [7,8], so would not
detect any shorter-term fluctuations in cognitive perform-
ance [9]. For example, cognitive function might fluctuate
alongside day-to-day changes in symptom levels or, less
dramatically, might be relatively improved during remit-
ted phases and relatively worse during relapse.
Understanding of cognition in schizophrenia could
clearly be improved by studies involving more extensive
repeated assessments, and more sensitive longitudinal
analyses. Given the clinical and cognitive heterogeneity in
schizophrenia, a within-subject, follow-through design is
necessary for individual differences to be more fully
understood. Comparisons of cross-sectional samples
from different points in the illness course are prone to
sampling biases, so cannot answer questions about factors
which may affect performance as individuals progress
through the illness. However practise effects may result in
artificial improvement in performance over repeated cog-
nitive assessments in longitudinal studies. Finally, since
longitudinal studies inevitably suffer from participant
attrition, appropriate statistical analyses are required that
make maximum use of all available data. Only then will
results reflect what is known about those who drop out of
the study as well as those who remain in and complete the
full protocol of assessments [10,11].
These issues are of relevance to current randomised con-
trolled trials of antipsychotic drugs. Compared with first-
generation antipsychotics (FGAs), the second-generation
drugs (SGAs) may ameliorate the cognitive deficit in
schizophrenia [12]. However, for cognitive performance
to become a consideration in clinicians' and patients'
choice of drugs, robust cognitive effects must be seen
when drugs are administered at a clinically appropriate
dose, rather than at a dose dictated by solely by a research
protocol.
This study aimed to investigate improvement and decline
of cognitive function in schizophrenia in pragmatic, sin-
gle-blind drug trials: the Cost Utility of the Latest Antipsy-
chotics in Severe Schizophrenia (CUtLASS) studies. In
CUtLASS, clinicians were given choice over the antipsy-
chotic drug and dosage used for each patient. Cognitive
change was characterised by a standardised neuropsycho-
logical assessment battery that was repeated four times
over the course of one year. The primary aim of this report
was to assess whether the group showed cognitive change
over time, and the extent to which this varied between
individuals. This was done using methods for modelling
individual differences in the context of group mean
effects: latent growth curve modelling. We predicted that
there would be no significant change over one year, since
the sample comprised patients with a generally chronic
and stable state of illness. Our analyses were opportunistic
on the collection of cognitive data on a non-randomly
selected sub-sample of trial participants, although this ini-
tiative was written in to the trial protocol. Our results do
not therefore inherit all the benefits of a fully-randomised
design, and we cannot rule out the impact of selection fac-
tors on our results (see later Discussion).
Methods
Study design
Full details of the CUtLASS trials have been published
elsewhere [13,14]. The present study concerns a sub-sam-
ple of patients who underwent additional cognitive inves-
tigations. Briefly, the CUtLASS studies were multi-centre
randomised controlled trials, which enrolled patients
from the UK National Health Service with DSM-IV schiz-
ophrenia, delusional disorder, or schizoaffective disorder.
CUtLASS I [14] compared FGA and SGA drugs in patients
whose current treatment was being changed because of
inefficacy or intolerability; CUtLASS II [13] compared
clozapine with other SGAs in people whose medication
was being changed because of poor clinical response to
two or more drugs. Clinicians were free to choose the spe-
cific drug from within the randomised class (FGA or SGA),
and the appropriate dosage.
In the main protocol, four clinical assessments were com-
pleted over the course of one year: at trial entry, and sub-
sequently at 12, 26 and 52 weeks. In this cognitive sub-
study, neuropsychological assessments were also com-
pleted at these four time-points. Patients were recruited
for the cognitive study from the London and Nottingham
centres, according to their willingness to take part in the
additional assessments.
The study was approved by the Local Research Ethics com-
mittees and informed consent was obtained from all par-
ticipants.
Neuropsychological assessment
The National Adult Reading Test [NART, [15]] was admin-
istered at the first assessment to yield an estimate of pre-
morbid IQ. Neuropsychological performance was
assessed using tests from the Cambridge Neuropsycholog-
ical Test Automated Battery (CANTAB) which previousPage 2 of 10
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schizophrenia [16-18]. The CANTAB motor control task
was used first on each occasion, to assess current motor
processing and to familiarise participants with the touch-
screen system. The remaining tests were then completed
in a fixed order, so that the pattern of available data would
be consistent between and within patients.
Spatial and pattern recognition memory [19]
These tasks require participants to remember a series of
five locations (spatial recognition) or 12 abstract patterns
(pattern recognition) presented on the screen. After a
short delay, participants choose which of a pair of loca-
tions/patterns they have seen before. This is repeated with
subsequent series. The percentage of correct responses is
recorded.
Spatial Working Memory (SWM) [19]
In this self-ordered search task, participants search boxes
to find hidden tokens. Participants are told they should
remember which boxes they have already looked in since
the token will never appear there again. Two outcome
measures are recorded: the total number of errors, and a
strategy score, reflecting the number of search sequences
that are begun in the same box. More efficient strategies
receive lower strategy scores.
Stockings of Cambridge (SoC) [20]
Based on the Tower of London task [21], this test assesses
planning ability. Subjects see two pictures of coloured
balls in 'snooker pockets', and asked to move the balls to
make one picture match the other. The minimum number
of moves required is shown on the screen during the task;
the number of optimal solutions, initial thinking time
before the first response at the four-move level, and sub-
sequent thinking time between responses at the four-
move level are recorded.
Variable transformations
One-sample Kolmogorov-Smirnov tests indicated that
four outcome variables were not normally distributed.
These were transformed to approximate normality before
analysis: SoC initial and subsequent thinking times and
the motor control task response times (square-root trans-
form), and spatial working memory strategy score
(squared).
Analysis
Choice of analysis
Longitudinal changes in cognition are usually examined
using repeated measures ANOVA but there are clear bene-
fits in using more sophisticated techniques [22]. Since this
sample contained missing data many participants would
be lost from the ANOVA analysis that could be imple-
mented in standard statistics packages such as SPSS. It was
clearly preferable to use more flexible longitudinal meth-
ods that could retain partially incomplete data. This
would maximise the power of the study and allow results
to include information from patients who dropped out of
the trials as well as those who completed the full protocol
[23]. Given the known heterogeneity of cognition in
schizophrenia, methods that allow consideration of indi-
vidual variation in the rate of cognitive change may also
be important. The chosen approach, encompassing these
advantages, was to use latent growth modelling (LGM) in
a structural equation modelling environment. Latent
growth models (also known as random effects models)
were defined and estimated using Mplus version 3.1 [24].
All models estimated in this paper could also be
approached from a multilevel/linear mixed modelling
perspective [23]. These models show great similarities and
equivalences [24] and we would expect similar conclu-
sions to be reached.
Latent growth modelling approach
For each individual, cognitive function is assumed to fol-
low a specified function of time, plus an error component
(or residual). Latent growth factors were applied in the
manner of a confirmatory factor analysis to account for
the temporal ordering and dependency among the repeat
observations. The parameterisation of the growth factors
is an attempt to smooth over the pattern of change
recorded by the observed measures to estimate the contin-
uous trajectory that might have given rise to the observa-
tions. Robust modelling of curvilinear change requires
larger samples or more repeated measures. We therefore
restricted our modelling to linear growth models where
individual trajectories were summarised by an intercept,
reflecting initial performance level, and a single slope,
reflecting linear rate of change over time in each depend-
ent variable.
An advantage of LGM is that individual variation can be
considered as well as group mean effects: inter-individual
differences in rate of change (slope) and initial status
(intercept) were estimated and the effects of demographic
and treatment variables in predicting individual differ-
ences assessed.
Modelling with covariates (conditional modelling)
Although initial models were performed unconditionally
(without covariates), subsequent modelling was per-
formed with covariates to improve the validity of the
model for cases with missing data (because they provide
information from which the model can predict the likely
pattern of missing data). Since attrition or change may be
related to covariates such as age, sex or drug class, inclu-
sion of these in the model improves the likelihood that
the model assumptions regarding missing data will be
met. Moreover this conditional modelling approach ena-Page 3 of 10
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characteristics might explain individual variation in inter-
cept and slope.
The effect of demographic characteristics and treatment
allocations on individuals' level and change in perform-
ance were investigated using multivariate outcome linear
regressions in conditional growth models. Modelled
intercept and slope parameters were regressed on dummy
variables to identify group differences. The numbers of
subjects involved in the study was too small to allow the
effects of individual drugs on cognition to be meaning-
fully examined, however binary dummy variables for drug
class (FGA [1,0] SGA [0,1] and clozapine [0,0]) were
included, along with age, sex, and NART-estimated pre-
morbid IQ. Effects of these covariates on intercept or slope
were considered significant if the Wald ratio (effect esti-
mate: standard error) was greater than 1.96, according to
a z-distribution.
Likelihood ratio tests were used to determine if the regres-
sion of covariates on intercept and slope terms improved
the fit of the model. It was significantly improved if the
deviance (-2 x the log-likelihood difference) between the
conditional model, and a model where regression of the
five covariates on intercept and slope terms was fixed to
zero exceeded 18.3 (χ2 statistic for p = 0.05 at 10 DF).
Modelling process
Model estimation was performed using maximum likeli-
hood. Indices of model fit based on the returned log-like-
lihood value were calculated directly by the programme
(Mplus Version 3.1). Maximum likelihood parameter esti-
mates and robust standard errors returned by the ESTIMA-
TOR = MLR option are reported; these are the default
options in Mplus. Partially incomplete data were included
via maximisation of the log-likelihood based on all indi-
vidual data contributions. Application of the Expectation-
Maximisation algorithm allows inclusion of all available
data, including patients who dropped out of the trials
assuming a Missing At Random mechanism [25]. Further
details of the model selection process are available from
the authors.
Missing data and dropout
In order to explore the likely validity of our modeling
assumption that the cognitive data are missing at random
(MAR), logistic regression was used to estimate the effects
of NART IQ, age, gender and clinical state at trial entry
(positive, negative and general scale scores from the Posi-
tive and Negative Syndrome Scale (PANSS, [26]) on the
probability of dropping out of the study. Since this only
characterises the impact of time invariant covariates on
remaining in the study, we also estimated wave on wave
logistic regression models to predict dropout at each cog-
nitive assessment from cognitive score(s) at the preceding
assessment.
Results
Patient characteristics and drug allocations
Ten subjects were enrolled into the cognitive study from
London and 48 from Nottingham, comprising 17 women
and 41 men in total. DSM-IV diagnoses were schizophre-
nia (n = 45), schizoaffective disorder (n = 9) and delu-
sional disorder (n = 4). Further characteristics are shown
in Table 1.
Cognitive performance during the CUtLASS trials
Performance at trial entry was within the range of pub-
lished results in schizophrenia [16-18]. There was consid-
erable variability of cognitive performance, both between
patients and within patients between testing sessions. Test
performance can be seen in Table 2. The cognitive study
suffered from considerable attrition, and patients were
also more likely to complete the earlier than later tests
within each session. Column 6 of Table 2 shows the pro-
portion of patients for whom complete data were availa-
ble.
Logistic regression analyses revealed that dropout from
the study was independent of NART IQ and all clinical
scores at trial entry, but related to sex and age. The was a
trend for men (β = 0.832; SE = 0.681, p > 0.05) and
younger individuals (β = -0.066; SE 0.045, p > 0.05) to be
more likely to drop out of the trial but in neither case was
the effect statistically reliable, probably due to the low
power of such analyses with our small sample size and the
number of dropouts in each analysis.
Table 1: Characteristics of the CUtLASS cognitive study sample 
at trial entry
Mean (SD) Range
Age (years) 41.9 (12.0) 22–67
Duration of illness (years) 16.5 (12.0) 1–46
PANSS Positive symptoms 16.6 (6.92) 7–37
PANSS Negative symptoms 22.0 (7.58) 7–42
PANSS General symptoms 34.5 (8.66) 7–56
Global Assessment of 
Function
43.3 (15.0) 17–66
NART premorbid IQ 105.6 (12.3) 87–123
Drug allocations FGA (n) SGA (n)
Droperidol (1) Clozapine (14)
Haloperidol (2) Quetiapine (4)
Sulpiride (10) Risperidone (4)
Thioridazine (1) Olanzapine (19)
Trifluoperazine (2)
Zuclopenthixol (1)Page 4 of 10
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tion was not significantly predicted by the preceding test
performance on any cognitive variables. In contrast, drop-
out at T4 was weakly predicted by performance at T3 on
spatial working memory errors (β = -0.04; SE = 0.02; p =
0.08) and strategy (β = -0.004; SE = 0.002; p = 0.02), and
by pattern recognition (β = -0.06; SE = 0.03 p = 0.04). In
each case, patients who dropped out at T4 had performed
better at T3 than those who stayed in. Although we cannot
infer anything about whether those who dropped out did
so because of the cognitive performance that they would
have achieved, had they not dropped out, these logistic
regression results and trends suggest to us that there is a
need for, and considerable value in including missing
data in the analyses under a MAR approach, since this will
reduce the bias that might otherwise result from failure of
the missing completely at random (MCAR) assumption,
which applies to a complete case only analysis.
Repeated measures ANOVAs on this small group with
complete data were severely underpowered to detect
change; nonetheless significant improvement was
detected in SoC subsequent thinking time (F = 4.31, DF
3,51, p < .01) and SWM strategy (F = 6.29, DF 3,34, p <
.01).
Latent growth modelling was conducted as described
above. Table 2 shows the estimated parameters of the
LGMs for each measure (see Additional Files 1 and 2 for
further details). For every variable, the intercept (initial
performance) differed reliably from zero. In all but two
cognitive variables (pattern recognition and motor
latency), the group mean slope also differed reliably from
zero, representing a significant improvement in cognitive
performance over time, with the exception of spatial rec-
ognition memory where a significant decline in perform-
ance was seen.
In all models there was significant within-group variation
in intercept, but contrary to expectations, there was no
reliable within-group variation in slope. For all measures,
the magnitude of the slope was small relative to the vari-
ance in intercept, implying that mean change is small,
compared with the individual differences in absolute per-
formance level.
Significant amounts of variance in intercept and slope
terms remained unexplained. The modelling process was
therefore repeated with covariates, to determine the extent
to which age, sex, NART-estimated IQ and treatment allo-
cation explained the variance in intercept and slope, and
any additional variance.
Effects of covariates including drug class on cognition
For each cognitive measure, age, sex, NART and drug class
were assessed as predictors of individual differences in
intercept and slope. These results are shown in Table 3;
the estimate and standard error of the effects of each cov-
ariate on intercept and slope are shown first, followed by
the percentage of variance explained (r2) for continuous,
Table 2: CUtLASS cognitive performance measures over one year, at 0,12, 26 and 52 weeks.
Group performance [Mean (SD)] Complete 
Data
LGM Parameters [Estimate(SE)] Correlation
Cognitive 
Measure
0 12 26 52 N 
(% of 
sample)
Intercept Slope Variance of 
Intercept
Variance of 
Slope
Intercept-
Slope
Motor control 
task (√ ms) 34.6 (5.4) 34.1 (5.8) 34.9 (6.9) 35.0 (6.9) 25 (43%) 3.45 (0.83) 0.07 (0.22) 23.0 (8.88) 0.50 (0.70) 0.15
Pattern 
recognition 
(% correct)
73.8 (16.5) 76.3 (17.0) 77.7 (17.2) 73.9 (17.1) 26 (45%) 74.7 (2.12) 0.17 (0.47) 209 (49.2) 4.22 (2.19) -0.14
Spatial 
recognition 
(% correct)
69.8 (14.3) 67.1 (16.2) 66.7 (16.1) 63.0 (16.5) 26 (45%) 69.2 (1.79) -1.21 (0.47) 101 (36.3) 0.70 (2.31) 0.71
SoC optimal 
solutions
6.22 (2.83) 6.86 (2.93) 6.93 (2.74) 7.06 (2.31) 20 (35%) 6.29 (0.37) 0.19 (0.07) 4.87 (1.54) 0.00 (0.10) -0.65
SoC initial 
thinking time 
(√ ms)
81.7 (28.7) 76.0 (34.3) 68.1 (39.4) 67.3 (27.8) 19 (33%) 78.9 (3.91) -2.69 (0.90) 400 (173) 19.0 (28.5) -0.18
SoC subsequent 
thinking time 
(√ ms)
50.0 (25.7) 44.4 (27.7) 33.1 (23.2) 32.1 (24.3) 18 (31%) 48.5 (3.34) -3.86 (0.75) 427 (162) 1.46 (9.37) -0.52
SWM strategy 
score (squared)
1509 (214) 1555 (356) 1409 (324) 1304 (272) 16 (28%) 1434 (44.4) -30.6 (9.94) 54.5 (20.3)# 3.03 (2.25)# -0.45
SWM Total 
Errors
53.2 (25.8) 48.7 (24.7) 40.8 (24.7) 43.7 (30.8) 15 (26%) 53.0 (3.58) -1.73 (0.74) 461 (130) 0.70 (4.79) 0.74
Means (SD) and repeated measures ANOVA results. Scores shown are transformed to approximate the normal distribution. # × 10-3Page 5 of 10
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bold are statistically significant (ratio of estimate: stand-
ard error > 1.96). The direction of effects on intercept and
slope are shown in the bottom two rows, describing vari-
ables that predict better performance at trial entry and
faster improvement over time.
Sex, age, or NART-IQ significantly predicted the intercepts
of all variables except SWM strategy. Allocation to the SGA
group affected the intercepts of SoC optimal solutions and
subsequent thinking times. Predictors of cognitive change
were less common, and were generally limited to age (see
Figure 1) and sex (see Figure 2). Treatment allocation
affected only one measure, SoC optimal solutions, where
those allocated to a FGA improved more quickly than
those allocated to other drugs (see Figure 3).
Likelihood ratio tests showed that covariates significantly
improved the fit of all models except SoC initial thinking
time (deviance = 7.46, required χ2 = 18.3).
Discussion
Conventional analysis using repeated measures ANOVA
revealed significant improvement over time in two varia-
bles (SoC subsequent thinking time and SWM strategy)
but was limited by the exclusion of up to 74% of cases due
to missing data. This level of attrition resulted in a loss of
power to just 17% for a cognitive change of 0.5 standard
deviations at an alpha level of 0.05. Latent growth model-
ling using maximum likelihood methods allowed inclu-
sion of all available data and consequently increased
power and representativeness, although our sample was
still somewhat selected. LGM revealed significant
improvement over time in all cognitive variables except
pattern recognition and motor latency, and spatial recog-
nition memory, which declined over time.
Traditional statistical techniques that only allow inclusion
of complete data cases may mask individual variations in
cognitive change, by reducing the power to detect reliable
individual or group differences, or limit generalisability,
due to exclusion of a non-random subset of participating
patients. Here, statistical modelling in a LGM framework
using maximum likelihood estimation enabled the per-
formance of those who dropped out of the study to be
included in analyses, and analysed alongside study com-
pleters. Longitudinal data of this kind benefit from careful
analysis, especially in small samples or where missing
data occurs.
Although unconditional LGM is an improvement over
techniques that exclude data with missing values, these
models must still be interpreted with caution since for all
cognitive measures, significant amounts of variance
remained unexplained. Conditional modelling, by
improving the likely validity of the missing data assump-
tions improved the fit of all models except one, and
should also have improved the external validity of the
study.
There was no clear pattern of factors that predicted cogni-
tive change throughout the study. In general, being young,
male, and of a higher NART IQ predicted better initial per-
formance. The effect of age on rate of change varied: in
some cases older patients improved less quickly, in others
more quickly, perhaps where younger patients had
already reached a performance limit (e.g. SoC subsequent
thinking time, Figure 1). Similarly, although women often
started with poorer performance they tended to improve
more quickly (Figure 2).
For two variables, (SoC optimal solutions and subsequent
thinking time) patients on second-generation drugs were
cognitively worse at trial entry. This probably reflects the
randomisation process of the two trials: half of those allo-
cated SGAs and all of those allocated to clozapine were
from the CUtLASS II trial of patients where at least two
previous antipsychotics had failed to control their symp-
toms, while this was not the case for any patient ran-
domised onto FGAs. Patients allocated to SGAs may
therefore have been, on average, more symptomatic, or ill
for longer than those randomised to FGAs.
Treatment allocation affected the rate of change on one
cognitive measure, with patients randomised to the FGA
group showing improved SoC performance more quickly
than patients allocated SGA drugs, including clozapine.
Although contrary to the general belief that SGAs improve
cognition more than FGAs [12,27] this is interesting since
CUtLASS I [14] found no evidence for the presumed ben-
efits of SGAs over FGAs in treatment efficacy. Overall,
drug class had little impact on cognition in this study,
although this may largely reflect a lack of power. Drug-by-
drug analyses, which may have been informative, were
not possible due to the small sample.
Consistent improvement was seen throughout the year in
the planning and working memory tasks, but not in spa-
tial or pattern recognition. One interpretation of this is
that patients benefited from practise only on tasks that
have some strategic component. This is interesting given
previous reports of a relative inability of patients with
schizophrenia to benefit from strategy training [28,29].
Another possibility is that the general clinical improve-
ment seen in the CUtLASS trials [13,14] affected memory
less than executive functions, which might be more sensi-
tive to changes in dopaminergic function. Either way,
given that a minimum of 12 weeks existed between assess-
ments, the significant improvements seen over time in the
planning and working memory tasks are noteworthy.Page 6 of 10
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pattern recognition, while decline was seen in spatial rec-
ognition. In contrast, healthy volunteers improve on pat-
tern recognition at a four-week retest while their
performance on spatial recognition remains stable over
time [30]. This could reflect structural changes such as the
grey matter reductions found in first-episode psychosis
[31-33], or alternatively, an acceleration of the normal
age-related worsening of memory. Some authors have
argued for accelerated cognitive decline in elderly schizo-
phrenia patients but this has usually been restricted to
executive functioning [34]. Moreover, recent research has
found no significant difference in age-related cognitive
decline in adults with schizophrenia compared with
healthy controls [35].
These findings may be limited by the drug trial context.
The CUtLASS trials had the advantage of randomised drug
class allocation, avoiding the problem in naturalistic stud-
ies where certain drugs may be prescribed for particular
groups. However, they were not designed with cognition
as the primary endpoint, so our results regarding the ran-
domised groups should be treated with caution: randomi-
sation may not be complete for this selected cognitive
sub-study. Nonetheless, since antipsychotic medication is
usually ignored in naturalistic studies of cognition, and
polypharmacy and changes of drug are not unusual in the
treatment of schizophrenia, [36,37] this group may not be
particularly unrepresentative of chronic schizophrenia.
In summary, both improvements and decline in cognition
may occur in established schizophrenia over one year.
However, cognitive change in established schizophrenia
is small when compared with the large differences in cog-
nitive function that exist between patients.
Conclusion
Both improvements and decline in cognition may occur
in established schizophrenia over one year. However, cog-
nitive change in established schizophrenia is small when
Table 3: Multivariate regression of covariates on latent growth models of cognitive measures in CUtLASS. 
Pattern 
Recognition
Spatial 
Recognition
SWM Errors SWM Strategy SoC Solutions SoC Initial 
Thinking
SoC 
Subsequent 
Thinking
Motor Latency
Est (SE) r2/d Est (SE) R2/d Est (SE) r2/d Est (SE) r2/d Est (SE) r2/d Est (SE) r2/d Est (SE) r2/d Est (SE) r2/d
Intercept:
NART-IQ 0.47 
(0.19)
0.31 0.21 
(0.18)
0.18 -1.08 
(0.29)
0.46 -0.08 
(0.05)
0.33 0.14 
(0.02)
0.60 -0.13 
(0.08)
0.25 -0.92 
(0.29)
0.41 -0.13 
(0.08)
0.25
Age -0.35 
(0.17)
0.29 -0.31 
(0.15)
0.32 1.03 
(0.25)
0.53 0.01 
(0.04)
0.03 -0.13 
(0.02)
0.63 0.14 
(0.07)
0.33 1.30 
(0.22)
0.69 0.14 
(0.07)
0.33
Sex 10.6 
(4.04)
0.73 -7.86 
(3.61)
0.69 14.8 
(6.43)
0.64 0.85 
(1.06)
0.35 -1.36 
(0.57)
0.55 3.04 
(1.71)
0.60 8.59 
(5.64)
0.38 3.04 
(1.71)
0.60
FGA 5.91 
(5.02)
0.41 -2.70 
(4.50)
0.24 -2.55 
(7.87)
0.11 -1.02 
(1.25)
0.42 -0.93 
(0.70)
0.38 2.67 
(2.08)
0.53 4.29 
(7.16)
0.19 2.67 
(2.08)
0.53
SGA 2.17 
(4.60)
0.15 -1.15 
(4.13)
0.10 12.55 
(6.81)
0.54 -0.32 
(1.02)
0.13 -1.46 
(0.61)
0.59 2.06 
(1.92)
0.41 21.8 
(6.24)
0.98 2.06 
(1.92)
0.41
Slope:
NART-IQ 0.02 
(0.05)
0.09 0.09 
(0.05)
0.59 -0.05 
(0.08)
0.21 -0.01 
(0.01)
0.19 -0.01 
(0.01)
0.31 0.03 
(0.02)
0.40 0.07 
(0.09)
0.21 0.03 
(0.02)
0.40
Age -0.08 
(0.04)
0.46 -0.01 
(0.04)
0.09 -0.02 
(0.07)
0.10 0.02 
(0.01)
0.44 0.00 
(0.01)
0.08 0.04 
(0.02)
0.55 -0.16 
(0.07)
0.55 0.04 
(0.02)
0.55
Sex 1.35 
(0.87)
0.68 -1.51 
(0.84)
1.05 -3.76 
(1.66)
1.72 0.01 
(0.04)
0.00 0.42 
(0.13)
0.55 -0.27 
(0.45)
0.32 -1.52 
(1.51)
0.44 -0.27 
(0.45)
0.32
FGA -0.27 
(1.12)
0.14 -0.46 
(1.08)
0.32 -1.29 
(2.05)
0.63 -0.22 
(0.25)
0.50 0.33 
(0.17)
0.96 -0.47 
(0.55)
0.56 -3.53 
(1.90)
1.03 -0.47 
(0.55)
0.56
SGA 0.77 
(1.01)
0.39 -1.02 
(0.99)
0.36 -1.40 
(1.70)
0.64 0.04 
(0.20)
0.08 0.12 
(0.15)
0.36 -0.01 
(0.52)
0.01 -3.21 
(1.67)
0.93 -0.01 
(0.52)
0.01
Better at 
trial entry
MEN, 
YOUNGER 
HIGHER IQ
MEN, 
YOUNGER
WOMEN, 
YOUNGER 
HIGHER IQ
- MEN, 
YOUNGER 
HIGHER IQ, 
SGA,
YOUNGER YOUNGER, 
HIGHER IQ
YOUNGER
Faster to 
improve
- - MEN YOUNGER WOMEN, FGA OLDER OLDER YOUNGER
Covariates are: NART-predicted IQ, age, sex, drug class [FGA,SGA,clozapine]. Regression of covariates on 'best-fit' latent growth models. Bold = Wald Ratio 
(Estimate: Standard Error) reliable at p < 0.05 (i.e. significant effect on growth factor). Effect sizes: r2 given for continuous covariates (age, NART); Cohen's d 
for categorical ones (sex, FGA, SGA)Page 7 of 10
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that exist between patients.
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